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Abstract 
Peptidylarginine  deiminase  type  4  (PADI4)  converts  arginine  residues  into  citrulline.  The 
current study focused on the expression of PADI4 in various subtypes of ovary cancers, and 
this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that 
originated  from  ovary  tumors.  We  utilized  immunohistochemistry,  real-time  PCR  and 
western blotting to analyze the expression of PADI4 in the tumor tissues and in the cell line 
that were cultured with estrodial-17β. PADI4 was detected in serious cystadenocarcinoma 
(n=39, positivity=100%), clear cell cancer (n=7, positivity= 100%), mucinous cystadenocar-
cinoma (n=6, positivity=100%), dysgerminoma (n=6, positivity=100%), squamous cell tumor 
(n=6, positivity=100%), sibnet-ring cell carcinoma (n=6, positivity=100%), endodermal sinus 
tumor (n=6, positivity=100%), germ cell tumors (n=6, positivity=100%) and immature tera-
toma (n=6, positivit y = 1 0 0 % ) .   H o w e v e r ,   P A D I 4   w a s   e i t h e r   n o t   d e t e c t e d   o r   d e t e c t e d   a t   l o w  
levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and 
normal ovarian tissue (n=11). For serious cystadenocarcinoma, all of the samples with high 
PADI4   e x p r e s s i o n   b e l o n g e d   t o   t h e   T 1   a n d   T 2   s t a g e s   o f   p T M N ,   w h e r e a s   a l l   o f   t h e   s a m p l e s   t h a t  
e x h i b i t e d   w e a k   o r   m o d e r a t e   P A D I 4   e x p r e s s i o n   b e l o n g e d   t o   t h e   T 3   a n d   T 4   s t a g e s .   P A D I 4   w a s  
evenly distributed in the cytoplasm of tumor cells of serious cystadenocarcinoma that were 
classified as being grade II and III by histopathological scoring. However, PADI4 showed 
g r a n u l a r   c e l l u l a r   d i s t r i b u t i o n   i n   t h e   t u m o r   t i s s u e s   t h a t   w e r e   i s o l a t e d   f r o m   g r a d e   I   c y s t a d e-
nocarcinoma. In addition, the PADI4 level was positively related with the ages of the patients 
that presented with serious adenocarcinoma (p=0.029). Real-time PCR and western blot 
analyses confirmed that PADI4 was expressed at higher levels in ovarian adenocarcinoma 
(n=8) compared to ovarian cystadenoma (n=5) (p< 0.05). T h e   s t u d y   a l s o   d e t e c t e d   a n   i n-
c r e a s e d   l e v e l   o f   P A D I 4   i n   S K O V -3   c e l l s   t h a t   w e r e   i n c u b a t e d   w i t h   e s t r o d ial-17β in the r a n g e   o f  
10
-12 t o   1 0
-4M.   T h e   r e s u l t s   s u g g e s t   a n   i m p o r t a n t   r o l e   f o r   P A D I 4   i n   t h e   t u m o r i g e n e s i s   o f   o v a r y  
cancers that are under the regulation of estrogen. 
Key  words: Peptidylarginine  deiminase  type  4  (PADI4/PAD4);  ovarian  cancer  (OCa);  estrodi-
al-17β. 
1. Introduction 
Peptidylarginine deiminase (PAD) conducts the 
post-translational modification of arginine into citrul-
l i n e   i n   t h e   p r e s e n c e   o f   C a 2+.   P A D I 4 ,   o n e   o f   t h e   f o u r  
P A D   i s o f o r m s ,   h a s   b e e n   c o n f i r m e d   t o   b e   a s s o c i a t e d  
with rheumatoid arthritis (RA) in some populations 
[1, 2]. The enzyme is significantly expressed in syn-
o v i a l   t i s s u e s   o f   R A   p a t i e n t s   a n d   w a s   l o c a t e d   i n   m o-
nocytes, macrophages, eosinophils and neutrophils of 
the affected tissue [3-7]. Some studies have indicated 
that  PADI4 antagonizes  the  methylation  of  histones Int. J. Biol. Sci. 2010, 6 
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via  deimination,  which  represses  hormone  (estro-
gen)-target transcription and interrupts cell apoptosis 
[8, 9]. 
Utilizing  immunohistochemistry  and  western 
blot analysis, we detected significant levels of PADI4 
expression  in  many  types  of  adenocarcinomas,  in-
cluding colon, duodenum, esophagus, fallopian tube, 
gall gladder, lung, ovary, parotoid, pancreas, prostate, 
rectum, small intestine, stomach, thyroid and uterus 
adenocarcinomas [10].  
Thus far, citrullination of histones, cytokeratin, 
antithrombin and fibronectin have been confirmed to 
be involved in abnormal apoptosis, high coagulation, 
and disordered cell proliferation and differentiation, 
a l l   o f   w h i c h   a r e   m a i n   f e a t u r e s   o f   m a l i g n a n t   t u m o r s   [ 8 ,  
1 0 ,   1 1 ] .   H o w e v e r ,   t h e r e   i s   c u r r e n t l y   n o t   e n o u g h   d a t a   t o  
c l a r i f y   t h e   p a t t e r n   o f   P A D I 4   e x p r e s s i o n   i n   v a r i o u s  
subtypes of tumors that have been isolated from the 
same organ, and there are no   r e p o r t s   t h a t   r e v e a l   t h e  
relationship between the expression of PADI4 and the 
resultant  clinical  implications.  All  of  these  issues 
c o u l d   f a c i l i t a t e   t h e   d i s c o v e r y   o f   t h e   m e c h a n i s m   u n-
derlying PADI4 activity in tumorigenesis. 
O v a r y   c a n c e r   ( O C a )   i s   t h e   f o u r t h  most frequent 
cause of cancer-related death among women [12].The 
incidence of OCa varies widely in frequency among 
different  geographic  regions  and  among  ethnic 
g r o u p s .   T h e   i n c i d e n c e   o f   O C a   i n c r e a s e s   w i t h   a g e ,   a s   i t  
i s   r e l a t i v e l y   r a r e   i n   w o m e n   y o u n g e r   t h a n 30 years of 
a g e   [ 1 3 ] .   A b o u t   t w o -thirds of patients with OCa show 
histological features that are consistent with stages III 
and IV (International Federation of Gynecology and 
Obstetrics,  FIGO).  These  patients  typically  have 
widespread  tumor  dissemination  within  the  abdo-
minal cavity and varying degrees of pleural effusion 
[ 1 4 ] .   T h e   c u r r e n t   s t u d y   i n v e s t i g a t e d   t h e   e x p r e s s i o n   o f  
P A D I 4   i n   v a r i o u s   s u b t y p e s   o f   O C a ,   w h i c h   w e r e   c a t e-
gorized into different grades and stages according to 
their histological features, an d   e x p l o r e d   h o w   P A D I 4  
expression is related to various aspects of clinical da-
t a .   P r e v i o u s   s t u d i e s   h a v e   s h o w n   t h a t   e s t r o g e n   m a y  
play an important role in OCa carcinogenesis [15]. To 
further understand the pathogenic mechanism of es-
trogen in the tumorigenesis   o f   O C a ,   t h e   p r e s e n t   s t u d y  
also investigated the implications of estrodial-17β in 
PADI4 expression utilizing cultured SKOV-3 cells that 
originated from the tumors.  
2. Materials and Methods  
2.1. Anti-PADI4 antibody preparation 
The  PADI4  antibody  was  prepared  by  immu-
nizing  rabbits  with  an  oligopeptide 
( F G D S C Y P S N D S R Q M H )   t h a t   i s   s p e c i f i c   f o r   a n   a m i n o  
a c i d   s e q u e n c e   o f   P A D I 4 ,   b u t   n o t   f o r   t h e   s e q u e n c e s   o f  
other  PAD  members.  The  immunospecificity  of  the 
antibody has been verified in our previous study [7]. 
2.2. Sample preparation  
S a m p l e s   o f   o v a r i a n   t u m o r s ,   i n c l u d i n g   8   s a m p l e s  
of ovarian adenocarcinoma and 5 samples of ovarian 
cystadenoma,  were  obtained  during  excision  surge-
ries in the Shandong Tumor Hospital (Jinan, China) 
a n d   T h e   F o u r t h   P e o p l e ’ s   H o s p i t a l   o f   Jinan  (Jinan, 
China). In addition, tissue arrays were generated that 
c o n t a i n e d   8 0   a n d   4 3   o v a r i a n   t i s s u e   s e c t i o n s   w e r e  
commercially  obtained  from  Chaoying  Bioscience 
(Shanxi, China) and Fanpu Bioscience (Guilin, China), 
respectively. The slides contained various tumor tis-
sues  including  serous  adenocarcinoma  (n=39),  clear 
cell  cancer  (n=7),  musinous  adenocarcinoma  (n=6), 
teratoma (n=6), dysgerminoma (n=6), squamous cell 
tumor  (n=6), sibnet-ring cell carcinoma (n=6), endo-
d e r m a l   s i n u s   t u m o r   ( n = 6 ) ,   g e r m   c e l l   tumors  (n=6), 
normal  ovarian  tissue  (n=11),  granulosa  cell  tumor 
(n=6) and immature teratoma (n=6). 
2.3. Total protein extraction and western blot 
analysis 
Ovary adenocarcinoma (n=8) and ovary cysta-
denoma (n=5)  were  determined  by  histological  me-
thods, and the pathological classification was deter-
mined  according  to  World  Health  Organization 
(WHO)  classifications.  These  sample  tissues  were 
collected during excision surgery. Two hundred mi-
crograms of the sample tissues were homogenized in 
Cell Lysis Solution (Sigma) and centrifuged at 16,000x 
g   f o r   5   m in at 4℃. The supernatant was collected after 
centrifugation,  and  the  protein  concentrations  were 
determined  using  a  BCA  protein  assay  kit  (Pierce). 
T h e   e x t r a c t   o f   t o t a l   p r o t e i n   w a s   s e p a r a t e d   b y   s o d i u m  
dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE)  and  transblotted  onto  a  nitrocellulose 
membrane (Amersham, USA). Western blot analysis 
was conducted using the anti-PADI4 antibody, with 
1000-fold dilutions. All primary and secondary anti-
bodies were diluted   i n   5 %   n o n f a t   d r y   s k i m   m i l k   i n  
T B S T ,   p H   7 . 6 ,   w h i c h   c o n t a i n e d   0 . 1 %   T w e e n   2 0 .   I m-
munoreactive  signals  were  detected  with  alkaline-
phosphatase-conjugated  secondary  antibodies  and 
visualized using a Western Blotting Luminol Reagent 
(Amsheram). The acquisition of   E C L   i m a g e s   w a s   c a r-
r i e d   o u t   w i t h   a   T y p h o o n   T r i o   ( G E   H e a l t h c a r e ,   U S A ) .  
The quantification of each sample was conducted us-
ing  ImageQuant5.2  software.  A  second  membrane 
w a s   p r e p a r e d   u s i n g   t h e   s a m e   p r o t o c o l   a s   t h e   p r i m a r y  
b l o t ,   a n d   t h i s   s e c o n d   m e m b r a n e   w a s   h y bridized with Int. J. Biol. Sci. 2010, 6 
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an anti-G A P D H   a n t i b o d y   ( S a n t a   C r u z )   t o   n o r m a l i z e  
the sample loading.  
2.4. Cell culture 
H u m a n   o v a r y   c a n c e r   c e l l s ,   S K O V -3,  were  cul-
tured in RPMI 1640 media, which was phenol red-free 
(Hyclone, Thermo) and supplemented with 10% fetus 
ox blood serum,  at 37℃ in a humidified atmosphere 
with 5% CO2. Estrodial-17β (Sigma) was added to the 
cultures at 10-4, 10-6, 10-8, 10-10 or 10-12 M final concen-
t r a t i o n s .   C e l l s   w e r e   i n c u b a t e d   f o r   3   d a y s .   T h e   c e l l s  
were  harvested  and  lysed  using  cell  lysis  buffer 
[20mM  Tris  PH7.5,  150mM  NaCl,  1%Triton  X-100, 
2.5mM  sodium  pyrophosphate,  1mM  EDTA,  1% 
Na3VO4, 0.5μg/ml leupeptin, 1mM phenylmethane-
sulfonyl  fluoride  (PMSF)].  The  concentration  of  the 
total protein extracts was determined by a Bradford 
protein assay. Western   b l o t   a n a l y s i s   w a s   p e r f o r m e d   a s  
described above. 
2.5. Immunohistochemistry 
Tissue  sections  were  de-paraffinized  and 
re-hydrated  using  standard  procedures.  Before  the 
anti-PADI4 antibody was applied, the tissue sections 
were heated at 95℃ for 10 min in Citrate Buffer Solu-
t i o n   ( S i g m a )   t o   r e p a i r   t h e   a n t i g e n .   T h e   t i s s u e   s e c t i o n s  
were then incubated with an Endogenous Peroxidase 
Inhibitor (MaixinBio, China) for 30 min at room tem-
perature. After washing with PBS buffer (NaCl 7.75 g, 
K2HPO4 1.5 g, KH2PO4 0.2 g in 1   L   d i s t i l l e d   w a t e r ,   p H  
7 . 6 ) ,   t h e   s e c t i o n s   w e r e   i n c u b a t e d   w i t h   t h e   a n t i -PADI4 
antibody overnight at 4℃. The immunoreaction was 
processed using the UltraSensitive TM S-P kit (Maix-
in-Bio,  China)  according  to  the  manufacturer’s  in-
structions,  and  the  immunoreactive signals were vi-
s u a l i z e d   u s i n g   a   D A B   s u b s t r a t e .   T h e   D A B   s u b s t r a t e  
stained the target protein yellow. Cell structures were 
counterstained with hematoxylin. A series of control 
slides were prepared as follows: (1) the slides were 
only  incubated  with  the primary antibodies, (2) the 
slides were only incubated with the secondary anti-
b o d i e s   o r   ( 3 )   t h e   s l i d e s   w e r e   i n c u b a t e d   w i t h   n o r m a l  
rabbit serum. 
2.6. Immunofluorescent Immunohistochemistry 
The tissue sections were processed as described 
above. After washing the tissue sections three times 
w i t h   P B S   b u f f e r ,   t h e   s e c t i o n s   w e r e   t r e a t e d   w i t h   g o a t  
pre-immune serum (Maixin-B i o ,   C h i n a )   f o r   3 0   m i n   t o  
elevate  the  specificity  of  the  immunoreaction.  The 
slides were incubated with the PADI4 antibody at 4℃ 
for 12 h and then washed with PBS. TRITC 5-goat anti 
rabbit IgG (ZSG-B I O ,   C h i n a )   w a s   a d d e d   t o   t h e   s l i d e  
a n d   i n c u b a t e d   f o r   4 0   m i n   a t   r o o m   t e m p e r a t u r e .   T h e  
immunofluorescent results were observed with a flu-
o r e s c e n t   m i c r o s c o p e   ( N i k o n ,   J a p a n ) .   I n   o r d e r   t o   d e-
termine the antibody specificity and optimize the an-
t i b o d y   d i l u t i o n ,   a   s e r i e s   o f   c o n t r o l   s l i d e s   w e r e   p r e-
pared as follows: (1) the slides were only incubated 
w i t h   t h e   p r i m a r y   a n t i b o d i e s ,   ( 2 )   t h e   s l i d e s   w e r e   o n l y  
incubated  with  the  secondary  antibodies  or  (3)  the 
slides were   i n c u b a t e d   w i t h   n o r m a l   r a b b i t   s e r u m   a n d  
goat serum.  
2.7. Quantitative Real-Time-PCR Analysis 
The  total  RNA  was  isolated  from  the  cultured 
SKOV-3 cells, ovary adenocarcinoma (n=8) and ova-
rian  cystadenoma  (n=5)  by  Trizol  (Invitrogen)  ac-
c o r d i n g   t o   t h e   m a n u f acturers’ protocols. The extracted 
RNA was reverse-t r a n s c r i b e d   i n   a   f i n a l   v o l u m e   o f   1 0  
u l   u s i n g   a   R N A   P C R   K i t   ( T a K a R a ) .   R e a l -time  PCR 
r e a c t i o n s   w e r e   c o n d u c t e d   u s i n g   a   L i g h t C y c l e r   2 . 0   I n-
strument  (Roche  Molecular  Biochemicals)  according 
to the manufacturer’s protocols. PCR was performed 
i n   a   1 0   u l   t o t a l   v o l u m e   t h a t   c o n t a i n e d   1   u l   o f   c D N A ,  
5 u l   o f   S Y B R   Green  Real-t i m e   P C R   M a s t e r   M i x  
( T o Y o B o ,   J a p a n )   a n d   1   u l   o f   e a c h   p r i m e r .   P C R   w a s  
c o n d u c t e d   w i t h   t h e   f o l l o w i n g   c o n d i t i o n s :   1 0   s   at 95℃; 
4 5   c y c l e s   o f   5   s   a t   6 0 ℃ and 10 s at 72℃; 30 s at 65℃. 
The level of β-actin mRNA was used as a reference to 
normalize for sample loading. For each tumor sample, 
t w o   r e a c t i o n s   w e r e   p e r f o r m e d   a t   t h e   s a m e   t i m e :   o n e  
reaction was to determine the mRNA level of the tar-
get gene and the second reaction was to determine the 
level  of  β-actin.  All  of  the  experiments  with  each 
s a m p l e   w e r e   c o n d u c t e d   i n   t r i p l i c a t e .   T h e   P C R   p r o d-
u c t s   w e r e   c o n f i r m e d   b y   m e l t i n g   c u r v e   a n a l y s i s .   T h e  
relative  expression  of  mRNA  was  calculated,  using 
the comparative thresho l d   c y c l e   ( C t )   m e t h o d ,   b y   f o l-
lowing  formula:  Ratio  =  2–ΔΔCt  =  2-ΔCt(sample), 
where ΔCt = Ct of target genes – Ct of endogenous 
control  gene  (β-actin)  [16].  The  relative  target  gene 
e x p r e s s i o n   w a s   n o r m a l i z e d   o n   t h e   b a s i s   o f   i t s   β -actin 
content. The primer sequences for the human PADI4 
gene were as follows: 
Forward  primer  for  PADI4: 
5’-GGCAAGTCTTCCAATGA-3’;  
Reverse  primer  for  PADI4: 
5’-CACATGCGATTGTATGC-3’;  
Forward  primer  for  human  β-actin:  5 ’
-TGGCACCCAGCACAATGAA-3’; 
Reverse  primer  for  human  β-actin: 
5’-CTAAGTCATAGTCCGCCTAGAAGCA-3. 
3. Results  
3.1. Immunodetection of PADI4 in ovarian tu-
mor tissues 
Immunohistochemistry and  immunofluorescent 
labeling was utilized to determine the expression of Int. J. Biol. Sci. 2010, 6 
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P A D I 4   i n   v a r i o u s   s u b t y p e s   o f   O C a .   T h e   e n z y m e   w a s  
detected in tumor cells in serous cystadenocarcinoma 
(39/39), clear cell cancer (7/7), mucinous cystadeno-
carcinoma (6/6), dysgerminoma (6/6), squamous cell 
tumor  (6/6),  sibnet-r i n g   c e l l   c a r c i n o m a   ( 6 / 6 ) ,   e n d o-
d e r m a l   s i n u s   t u m o r   ( 6 / 6 ) ,   g e r m   c e l l   t u m o r s   ( 6 / 6 )   a n d  
immature  teratoma (6/6). However, PADI4 was not 
d e t e c t e d   i n   t u m o r   c e l l s   f r o m   g r a n u l o s a   c e l l   t u m o r  
(0/6), malignant thecoma (0/6) and normal ovarian 
tissue (n=11). 
I n   m o s t   c a s e s ,   P A D I 4   w a s   l o c a t e d   i n   t h e   c y t o p-
l a s m   o f   t h e   t u m o r   c e l l s .   F o r   s o m e   s a m p l e s ,   s u c h   a s  
endodermal  sinus  tumor  (6/6)  and  dysgerminoma 
( 6 / 6 ) ,   P A D I 4   w a s   p r e s e n t   i n   t h e   n u c l e u s   o f   t h e   t u m o r  
cells.  The  enzyme  was  not  significantly  detected  in 
normal ovary tissues (n=11). No immuno-signal was 
observed in the negative controls that were incubated 
without  the  primary  or  secondary  antibodies.  The 
results  of  the  immunohistochemistry  are  shown  in 
Fig. 1. 
T h e   e x p r e s s i o n   o f   P A D I 4   w a s   a l s o   e x a m i n e d  
using the immunofluorescent method, and the results 
c a n   b e   s e e n   i n   F i g .   1 .   I n   o r d e r   t o   e v a l u a t e   t h e   l e v e l   o f  
PADI4  expression,  a  semi-quantitative  scoring  sys-
tem, which was based on the protocol of Koensgen’s 
study  [ 1 7 ] ,   w a s   u s e d   t o   a n a l y z e   t h e   r e s u l t s   o f   t h e  
immunofluorescent labeling. The scoring system con-
siders the following percentages: 0% positive staining 
cells = 0 ,   < 1 0 %   =   1 ,   1 0 -50% = 2, 51-80% = 3, and >80% 
= 4. The scoring system also accounts for the intensity 
of the staining as follows: negative staining = 0, low 
staining = 1, moderate staining = 2 and strong staining 
= 3. The expression level was determined by multip-
lying  these  two  scoring  indices  and  the  expression 
level  was  grouped  into  the  following  categories:  0 
(no), 1–4 (low), 5–8 (moderate) and 9–12 (strong). The 
semi-quantitative  analysis  of  PADI4  expression  in 
tumor tissues is shown in Table 1. 
According to the clinical prognosis, serous cys-
tadenocarcinoma (n=39) were classified into either T1 
(n=13), T2 (n=10), T3 (n=14) or T4 (n=2) stages based 
on  the  standard  of  Pathological  Tu-
mor-Node-M e t a s t a s i s   ( p T N M ) .   A l l   8   o f   t h e   s a m p l e s  
that had high expression of PADI4 (score ≥9)  were 
c l a s s i f i e d   a s   b e l o n g i n g   t o   t h e   T 1   ( n = 4 )   o r   T 2   ( n = 4 )  
stages,  whereas  16  samples  that  were  classified  as 
b e l o n g i n g   t o   t h e   T 3   ( n = 1 4 )   o r   T 4   ( n = 2 )   s t a g e s   e x h i-
bited  weak  (score  ≤4)  or  moderate  (4<score  ≤8) 
PADI4  expression.  Based  on  the  histopathological 
features,  the  serous  cystadenocarcinoma  samples 
w e r e   c l a s s i f i e d   i n t o   g r a d e   I   ( n = 6 ) ,   g r a d e   I I   ( n = 1 2 )   a n d  
g r a d e   I I I   ( n = 2 2 ) .   T h e   e x p r e s s i o n   o f   P A D I 4   w a s   e v e n l y  
d i s t r i b u t e d   i n   t h e   c y t o p l a s m   o f   t u m o r   c e l l s   f r o m   1 4  
s a m p l e s ,   1 2   o f   w h i c h   w e r e   c l assified as the grade III 
and 2 samples were classified as grade II. The expres-
sion of PADI4 in the other 25 samples, which were 
classified as grade I, showed a granular shape of cel-
lular distribution. The immunosignal of PADI4 in the 
sections that were grades II and III (score ≥9) were 
significantly  stronger  than  the  immunosignal  from 
sections that were grade I (1<score  ≤8). The  immu-
n o h i s t o c h e m i c a l   r e s u l t s   a r e   s h o w n   i n   F i g .   2 .   I n   a d d i-
tion, PADI4 levels were positively related to the ages 
of  the  patients  with  serous  adenocarcinomas 
( p = 0 . 0 2 9 ) .   T h e   P A D I 4   e x p r e s s i o n   l e v e l   i n   s e r o u s   c y s-
tadenocarcinomas is shown in Table 2, and the data 
suggests that the expression level and cellular distri-
b u t i o n   o f   P A D I 4   a r e   r e l a t e d   t o   t h e   c l i n i c a l   o u t c o m e s  
and histopathologic grades of the tumor. There was 
no  significant  association  between  the  PADI4  level 
a n d   e i t h e r   l y m p h   n o d e   m e t a s t a s i s   o r   d i s t a n c e   m e t a s-
tasis,  which  are  two  parameters  that  are  associated 
with the clinical prognosis related to the tumors.  
 
Table 1. Expression of PADI4 in various subtypes of ova-
rian cancers 
Tissue type\Expression level 
 
No 
Score 
(0) 
Low 
Score 
(1-4) 
Mod-
erate 
Score 
(5-8) 
Strong 
Score 
(9-12) 
Total 
serous adenocarcinoma 
(n=39) 
 0  12  19  8  39 
clear cell cancer (n=7)  0  7  0  0  7 
musinous adenocarcinoma 
(n=6) 
0  0  4  2  6 
teratoma (n=6)  0  4  2  0  6 
dysgerminoma (n=6)  0  0  5  1  6 
squamous cell tumor (n=6)  0  0  2  4  6 
endodermal sinus tumor 
(n=6) 
0  5  1  0  6 
sibnet-ring cell carcinoma 
(n=6) 
0  0  4  2  6 
germ cell tumors (n=6)  0  6  0  0  6 
granulosa cell tumor (n=6)  6  0  0  0  6 
malignant thecoma (n=6)  6  0  0  0  6 
normal ovarian tissue (n=11)  11  0  0  0  11 
Total  23  37  41  22  123 
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Fig. 1.   I m m u n o d e t e c t i o n   o f   P A D I 4   i n   v a r i o u s   k i n d s   o f   o v a r i a n   t u m o r s   b y  immunohistochemistry (A) and immunofluorescent 
labeling (B). 1 serous adenocarcinoma, 2 mucinous adenocarcinoma, 3 immature teratoma, 4 dysgerminoma, 5 clear cell 
cancer, 6 endodermal sinus tumor, 7 sibnet-r i n g   c e l l   c a r c i n o m a ,   8   s q u a m o u s   c e l l   t u m o r ,   9   m a l i g n a n t   t h e c o m a ,   1 0   g r a n u l o s a  
cell tumor, 11-12 ovary cystadenoma. (SP×400) Int. J. Biol. Sci. 2010, 6 
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Fig. 2.   I m m u n o d e t e c t i o n   o f   P A D I 4   i n   a   s e r o u s   a d e n o c a r c i n o m a   t h a t   w a s   f o u n d   t o   b e   d i f f e r e n t   b a s e d   o n   t h e   h i s t o p a t h o-
logical classification by immunohistochemistry (A) and immunofluorescent labeling (B). PADI4 showed an even cellular 
d i s t r i b u t i o n   i n   t u m o r   c e l l s   f r o m   a   s e r o u s   a d e n o c a r c i n o m a   t h a t   w e r e   c l a s s i f i e d   a s   b e i n g   g r a d e   I I   ( 1 )   a n d   I I I   ( 2 ) ,   a n d   P A D I 4   w a s 
f o u n d   t o   h a v e   a   g r a n u l a r   s h a p e   o f   c e l l u l a r   d i s t r i b u t i o n   i n   t u m o r   c e l l s   f r o m   a   s e r o u s   a d e n o c a r c i n o m a   t h a t   w a s   g r a d e   I   ( 3 ,   4 ) .  
PADI4 expression was significantly stronger in sections 1 and 2 compared to the expression in sections 3 and 4. (SP×400) 
 
Table 2. The expression of PADI4 in serous cystadenocarcinoma 
Patients (n=39)  Age  (years)  Tumor Stage 
(FIGO) 
pTNM  
(T1, T2, T3, T4) 
pTNM (N0, N1)  pTNM (M0, M1)  Expression Level of 
PADI4 
1  57  Ⅱ  T1  N0  M0  6 
2  57  Ⅱ  T3  N0  M0  8 
3  43  Ⅲ  T3  N1  M0  6 
4  54  Ⅰ  T1  N0  M0  2 
5  63  Ⅲ  T2  N1  M1  4 
6  46  Ⅲ  T3  N0  M0  6 
7  54  Ⅲ  T3  N0  M0  4 
8  49  Ⅲ  T2  N0  M0  12 
9  39  Ⅲ  T4  N1  M1  6 
10  42  Ⅲ  T2  N0  M0  4 
11  50  Ⅲ  T1  N0  M0  9 
12  49  Ⅲ  T3  N1  M0  8 
13  62  Ⅲ  T2  N0  M0  9 
14  26  Ⅰ  T1  N0  M0  2 
15  47  Ⅰ  T1  N0  M0  6 
16  47  Ⅲ  T1  N0  M0  12 
17  51  Ⅰ  T3  N1  M0  8 
18  55  Ⅲ  T2  N0  M0  12 
19  46  Ⅲ  T2  N1  M0  6 
20  57  Ⅲ  T3  N1  M0  8 
21  75  Ⅲ  T3  N1  M0  8 
22  69  Ⅲ  T1  N0  M0  9 
23  30  Ⅲ  T1  N0  M0  2 
24  42  Ⅱ  T3  N1  M0  2 
25  22  Ⅰ  T2  N0  M0  6 
26  32  Ⅱ  T1  N0  M0  4 
27  48  Ⅱ  T1  N0  M0  4 
28  65  Ⅲ  T3  N1  M0  6 
29  38  Ⅲ  T3  N1  M0  8 
30  51  Ⅲ  T2  N0  M0  12 
31  65  Ⅱ  T3  N0  M0  12 
32  26  Ⅱ  T3  N1  M0  8 
33  55  Ⅱ  T1  N0  M0  6 
34  49  Ⅲ  T2  N0  M0  3 Int. J. Biol. Sci. 2010, 6 
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35  46  Ⅲ  T3  N1  M0  8 
36  63  Ⅲ  T2  N0  M0  8 
37  37  Ⅱ  T4  N1  M1  4 
38  55  Ⅱ  T1  N0  M0  6 
39  55  Ⅱ  T1  N0  M0  4 
*: T1: tumor limited to the ovaries; T2: tumor involved with one or both ovaries with pelvic extension; T3: tumor involved with one or both 
ovaries with microscopically confirmed peritoneal metastasis outside of the pelvis; T4: peritoneal metastasis that extended beyond the pelvis 
by more than 2 cm in its greatest dimension. 
*: N0: no lymph node metastasis; N1: regional lymph node metastasis   
*: M0: no distant metastasis; M1: distant metastasis (excludes peritoneal metastasis) 
 
3.2. Quantification of PADI4 expression in ova-
rian tumors by western blotting analysis and 
real-time PCR 
T h e   l e v e l   o f   P A D I 4   i n   t h e   o v a r y   t u m o r s   w a s   d e-
termined by western blotting analysis. We analyzed 8 
samples of ovarian adenocarcinoma and 5 samples of 
o v a r y   c ystadenoma. Western blot detected an increase 
i n   t h e   l e v e l   o f   P A D I 4 ,   w h i c h   h a d   a   m o l e c u l a r   w e i g h t  
o f   6 7   k D a ,   i n   O C a   c o m p a r e d   t o   l e v e l s   d e t e c t e d   i n   t h e  
ovarian  cystadenoma  (p 
<0.05).  The  results  are 
shown in Fig. 3A and 3B.  
T r a n s c r i p t i o n   o f   P A D I 4   w a s   q u a n t ified  by 
real-time  quantitative  PCR.  All  of  the  OCa  samples 
exhibited a higher degree of PADI4 expression, com-
p a r e d   w i t h   t h e   l e v e l   o f   P A D I 4   e x p r e s s i o n   o b s e r v e d   i n  
the ovary cystadenomas. We did detect a low level of 
P A D I 4   e x p r e s s i o n   i n   5   s a m p l e s   f r o m   t h e   o varian cys-
tadenoma (p <0.05). The results are shown in Fig. 3C.  
  
Fig. 3.   ( A )   T h e   l e v e l s   o f   P A D I 4  
in ovarian adenocarcinoma and 
ovarian  cystadenoma  were 
analyzed by western blotting. 
( B )   T h e   e x p r e s s i o n   o f   P A D I 4   i n  
ovarian adenocarcinomas (lane 
1, n=8) was normalized to the 
expression  of  GAPDH,  and 
compared with the expression 
of  PADI4  in  ovarian  cystade-
n o m a   ( l a n e   2 ,   n = 5 ) .   T h e   r e s u l t s  
indicated that PADI4 expres-
sion was significantly increased 
in  ovarian  adenocarcinoma 
compared  to  ovarian  cysta-
denoma. (p=0.023< 0.05). (C) 
Real-t i m e   P C R   w a s   u s e d   t o  
measure  the  levels  of  PADI4 
mRNA  in  ovarian  adenocar-
c i n o m a   ( l a n e   1 ,   n = 8 )   a n d   o v a-
rian cystadenoma (lane 2, n=5). 
The expression of PADI4 was 
normalized to the expression 
of  β-actin.  The  results  indi-
cated  that  PADI4  expression 
was  significantly  increased  in 
ovarian  adenocarcinoma 
compared to the expression in 
ovarian cystadenoma (p=0.015< 0.05). 
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3.3. Expression of PADI4 in cultured human 
SKOV-3 cells that were cultured with estrogen.  
The  total  protein  was  extracted  from  SKOV-3 
cells that were incubated with estrodial-17β and the 
P A D I 4   e x p r e s s i o n   w a s   a n a l y z e d   b y   w e s t e r n   b l o t t i n g  
using an anti-PADI4 antibody. A band of PADI4 pro-
tein, which was 67 kDa, was detected in the cultured 
c e l l s   i n   p r e s e n c e   o f   e s t r o g e n .   T h i s   b a n d   w a s   a l s o  
p r e s e n t   i n   t h e   c o n t r o l s   t h a t   d i d   n o t   r e c e i v e   e s t r o g e n  
treatment  and  were  maintained  in  phenol  red-free 
media. The expression of β-a c t i n   w a s   u s e d   a s   a   r e f e r-
ence. The level of PADI4 was significantly increased 
with dilutions of estrodial-17β at 10-4,  10-6,  10-8, 10-10 
and 10-12 M concentrations. The level declined when 
t h e   c o n c e n t r a t i o n   o f   e s t r o g e n   w a s   d i l u t e d   t o   1 0 -12 M, 
b u t   t h e   l e v e l   o f   P A D I 4   e x p r e s s i o n   w a s   s t i l l   h i g h e r   t h a n  
the levels   o b s e r v e d   i n   t h e   c e l l s   t h a t   d i d   n o t   r e c e i v e  
e s t r o g e n   t r e a t m e n t   ( p   = 0 . 0 3 4 ) .   T h e   r e s u l t s   a r e   s h o w n  
in Fig. 4.  
T h e   t r a n s c r i p t i o n   o f   P A D I 4   i n   c u l t u r e d   c e l l s   w a s  
qualified  by  real-time  quantitative  PCR.  The  tran-
scription  of  β-actin  was  used  as  a  reference.  The 
m R N A   l e v e l   o f   P A D I 4   w a s   i n c r e a s e d   f o l l o w i n g  
treatments  with  estrogen,  which  corresponded  with 
t h e   r e s u l t s   f r o m   t h e   w e s t e r n   b l o t   a n a l y s i s .   T h e   r e s u l t s  
of the quantitative PCR are shown in Fig. 5. 
 
 
   
Fig. 4. Western b l o t t i n g   w a s   u s e d   t o   a n a l y z e   P A D I 4   e x p r e s s i o n   i n   S K O V -3 cells that were cultured with either estrodial-17 
(10
-4, 10
-6, 10
-8, 10
-10, 10
-12 M) or controls that were cultured without estrogen treatment in phenol red-free media. The 
expression of PADI4 in SKOV-3 was normalized to the expression of β-actin. A shows the western blotting results and B 
shows the relative levels of PADI4 in the cultured cells. The results indicate that PADI4 expression is increased with dilu-
t i o n s   o f   e s t r o g e n   t h a t   r a n g e   f r o m   1 0 -4   M   t o   1 0 -1 2   M   c o m p a r e d   t o   t h e   P A D I 4   e x p r e s s i o n   l e v e l s   i n   t h e   c o n t r o l   c e l l s   ( w i t h o u t  
estrogen treatment / phenol red-free media) (p=0.0057). Int. J. Biol. Sci. 2010, 6 
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Fig. 5. Real-tim e   P C R   m e a s u r e d   t h e   l e v e l   o f   P A D I 4   m R N A   i n   S K O V 3   c e l l s   t h a t   w e r e   c u l t u r e d   w i t h   e s t r o d i a l -17β at 
concentr a t i o n s   o f   1 0
-4, 10
-6, 10
-8, 10
-10 and 10
-12 M and control cells that were cultured without treatments of estrogen in 
phenol red-free media. The results indicate that PADI4 had increased expression with dilutions of estrogen that ranged 
between 10
-4 M and 10
-12 M, c o m p a r e d   t o   t h e   e x p r e s s i o n   o f   P A D I 4   i n   t h e   c o n t r o l   c e l l s   ( w i t h o u t   e s t r o g e n   t r e a t m e n t   i n  
phenol red-free media) (p=0.0063< 0.01). 
 
4. Discussion  
I n   t h e   p r e s e n t   s t u d y ,   P A D I 4   e x p r e s s i o n   w a s  
analyzed  using  immunohistochemistry  and  immu-
nofluorescent  labeling  in  a  cohort  of  ovarian  tumor 
forms.  In  comparison  to  benign  and  normal  ovary 
tissues,  the  expression  of  PADI4  was  significantly 
i n c r e a s e d   i n   t u m o r   c e l l s   f r o m   m o s t   o f   t h e   O C a   s u b-
types, including serous cystadenocarcinoma, clear cell 
cancer,  metastatic  adenocarcinoma,  metastatic  sib-
net-ring  cell  carcinoma,  dysgerminoma,  mucinous 
cystadenocarcinoma,  endodermal  sinus  tumor, 
squamous cell tumor, germ cell tumors and immature 
teratoma. However, PADI4 expression was either not 
detected  or detected  at low  levels in  granulosa  cell 
tumor, malignant thecoma, ovarian cystadenoma and 
n o r m a l   o v a r y   t i s s u e s .   O u r   r e a l -time PCR and western 
blot analysis confirmed that PADI4 was significantly 
expressed in ovary adenocarcinoma but maintained a 
l o w   l e v e l   o f   e x p r e s s i o n   i n   o v a r y   c y s t a d e n o m a .   A l l   o f  
t h e s e   f i n d i n g s   s u g g e s t   t h a t   P A D I 4   m a y   p l a y   a   r o l e   i n  
t h e   t u m o r i g e n i c   p r o c e s s ,   c o u l d   b e   c o n s i d e r e d   a n   i m-
munohistochemical  barometer  to  distinguish  tumor 
c e l l s   f r o m   n o n -t u m o r   c e l l s ,   a n d   P ADI4 could be uti-
lized to define the tissue structure of tumors.  
The effect of estrogen on tumorigenesis in OCa 
c e l l s   h a s   a r o u s e d   a t t e n t i o n   i n   t h e   p a s t   f e w   y e a r s .   W i t h  
MCF-7   c e l l s ,   w h i c h   w e r e   o r i g i n a t e d   f r o m   h u m a n  
b r e a s t   c a n c e r   t i s s u e ,   D o n g   e t   a l .   f o u n d   t hat estrogen 
enhanced  PADI4  expression  through  both  classical 
and non-classical transcription factor pathways. This 
group also reported that activator protein-1, Sp1/Sp3 
and nuclear factor-Y   a r e   t h e   c i s -acting factors that are 
r e s p o n s i b l e   f o r   t h e   b a s a l   a n d   the  E2-induced  tran-
s c r i p t i o n   o f   P A D I 4   i n   a n   E R -dependent manner [18]. 
With cultured SKOV-3 cells, which originated from 
O C a ,   w e   f o u n d   t h a t   P A D I 4   h a d   i n c r e a s e d   e x p r e s s i o n  
that corresponded with a decline in the concentrations 
of  estrodial-17β  within  the  range  of  10-4  to  10-10  M. 
These  findings  suggest  that  estrogen,  at  these  con-
centrations, may significantly elevate PADI4 expres-
sion in OCa. The physiological level of estrodial-17β 
in  healthy  women  ranges  between  10-8  and  10-10  M 
[19]. The level of estrogen declines in most postme-
nopausal women. Previous publications have shown 
t h a t   t h e   l e v e l   o f   e s t r o g e n   c a n   d e c l i n e   t o   1 0 -10  M  in 
women during their postmenopausal stage of life [20]. 
Our correlation analysis indicated that a significant 
association existed between the PADI4 level and the 
a g e   o f   t h e   p a t i e n t s ,   w h i c h   c o r r e s p o n d s   t o   t h e   r e s u l t s  
s h o w n   i n   o u r   c e l l   c u l t u r e   s t u d i e s   a n d   s u g g e s t s   t h a t  
elderly  patients  may  synthesize  higher  levels  of 
P A D I 4   c o m p a r e d   t o   y o u n g e r   p a t i e n t s .   T h e  
dose-dependent  reverse  correlation  of  β-estrodial Int. J. Biol. Sci. 2010, 6 
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concentrations and PADI4 expression indicated that 
PADI4 may participate in tumorigenesis, under the 
regulation of estrogen, as the estrogen levels decline 
w i t h   a g e .   T h i s   m a y   b e   e s p e c i a l l y   t r u e   i n   p o s t m e n o-
p a u s a l   w o m e n .   P A D I 4   e x p r e s s i o n   m a y   a c c o u n t   f o r   t h e  
age factor in Oca. The highest level of PADI4, which 
was stimulated at the 10-10 M concentration of estro-
gen, may contribute to the observation that postme-
n o p a u s a l   w o m e n   a r e   m o s t   s u s c e p t i b l e   t o   O c a .   T h e  
function  of  estrogen  is  very  complicated,  in  vivo. 
Thus,  estradiol-17β  at  the  different  concentrations 
used in the current study, has revised the effects on 
PADI4  expression.  Further  studies  are  needed  to 
s t u d y   t h e   r e g u l a t o r y   m e c h a n i s m   o f   e s t r o g e n   o n   t u-
morigenesis in Oca. 
Ovary cancers were categorized, based on their 
embryonic  development,  into  three  subgroups  in-
cluding epithelial tumors, germocyte tumors and sex 
cord mesenchyma tumors. Serous cystadenocarcino-
ma,  musinous  cystadenocarcinoma  and  clear  cell 
cancer belong to the epithelial tumor category. Dys-
germinoma,  immature  teratoma  and  endodermal  si-
nus tumor belong to the germocyte tumor category. 
Granulosa cell tumor and malignant thecoma belong 
t o   t h e   s e x   c o r d   m e s e n c h y m a   t u m o r   c a t e g o r y .   I n   t h e  
p r e s e n t   s t u d y ,   a l l   o f   t h e   O C a   s u b t y p e s ,   e x c e pt granu-
losa cell tumors and malignant thecomas, exhibited 
s i g n i f i c a n t   e x p r e s s i o n   o f   P A D I 4 .   I n   t h e   o v a r i e s ,   g r a-
n u l o s a   c e l l s   a r e   t h e   m a i n   s o u r c e   o f   e s t r o g e n   [ 2 1 ] ,   a l-
though  malignant  thecomas  also  have  the  ability  to 
synthesize  estrogen  [22].  These  facts  suggested  that 
P A D I 4   m i g h t   b e   e x p r e s s e d   i n   t u m o r s   t h a t   o r i g i n a t e d  
f r o m   t h e   e p i t h e l i a l   c e l l s   a n d   g e r m c y t e s ,   b u t   n o t   i n  
estrogen-producing cells. This analysis is consistent 
with  our  observation  that  estrogen,  at  the  low  con-
centrations tested, may significantly stimulate PADI4 
expression in the cultured SKOV-3 cells.  
O t h e r   s t u d i e s   h a v e   a l s o   f o u n d   t h a t   P A D I 4   w a s  
related to the tumorigenic process, although the prior 
s t u d i e s   d i d   n o t   r e p o r t   a n   o v e r -expression of PADI4 in 
the various tumor tissues. Cuthbert et al. and Wang et 
a l .   f o u n d   t h a t   c i t r u l l i n a t i o n   o f   P A D I 4   p r e v e n t e d   a r g i-
nine methylation of histone H3 and H4 during tran-
scriptional activation of estrogen-responsive genes [8, 
9 ] .   Y a o   e t   a l .   a n d   L i   e t   a l .   r e p o r t e d   t h a t   P A D I 4   r e-
pressed  the  expression  of  p53-mediated  genes,  in-
cluding OKL38, p21, CIP1 and WAF1, by deiminasing 
the  methylated  arginine  sites  in  histone  H3.  This 
consequently interrupted apoptotic processes and the 
cell cycle [23 24]. Disrupted apoptosis and disruptions 
t o   t h e   c e l l   c y c l e   a r e   t h e   m a i n   f e a tures of tumor cells 
[25]. When our results and the previous findings of 
others are combined, the cumulative results suggest 
that PADI4 may be involved in OCa tumorigenesis by 
antagonizing the regulation of p53, which results in 
the  disruption  of  tumor  suppressor  genes  that  are 
mediated by estrogen. 
T o   s u m m a r i z e ,   t h e   p r e s e n t   s t u d y   u s i n g   i m m u-
nohistochemistry,  western  blot  analysis,  real-time 
PCR and cell culture, identified an increase in the ex-
p r e s s i o n   o f   P A D I 4   i n   m a n y   t y p e s   o f   O C a .   T h e   e x p r e s-
sion level of P A D I 4   i n   o v a r y   t u m o r   t i s s u e s   w a s   r e l a t e d  
to the age of the patient, the histopathological classi-
f i c a t i o n   o f   t h e i r   r e s p e c t i v e   t u m o r s   a n d   s o m e   o f   t h e i r  
clinical outcomes when the patients were affected by 
serous  adenocarcinomas.  Our  study  also  indicated 
that low concentrations of estrogen can stimulate the 
e x p r e s s i o n   o f   P A D I 4   i n   o v a r y   t u m o r   t i s s u e s .   T h e  
a b o v e   r e s u l t s   s u g g e s t   a n   i m p o r t a n t   r o l e   f o r   P A D I 4   i n  
O C a   t u m o r i g e n e s i s   t h a t   i s   u n d e r   t h e   r e g u l a t i o n   o f  
estrogen. 
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